Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization.
Walgreens Boots Alliance schedules Fourth Quarter and Fiscal 2019 Earnings Announcement for October 28, 2019
DEERFIELD, Ill.–(BUSINESS WIRE)–Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fourth quarter and fiscal 2019 earnings results at 7
Aerie Pharmaceuticals seeks from FDA permission to produce Rocklatan in its Athlone Ireland Facility
Aerie Pharmaceuticals has submitted a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA), to be allowed to produce Rocklatan in Ireland, to be sold USA.
Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis
Nanobiotix’s radioenhancer NBTXR3 study showed encouraging results for Hepatocellular Carcinoma (HCC) patients, which are significant as they increase the scope of patients NBTXR3 may treat beyond Soft Tissue Sarcoma and Head and Neck cancer.
Transgene has posted net loss amounted to €15.3 million for the first half of 2019 compared to €14.9 million for the same period in 2018, while its cash, cash equivalents and other financial assets amounted to €12.8 million versus €16.9 million as of December 31, 2018.
NICE recommends Takhzyro injection as an option for preventing recurrent attacks of hereditary angioedema (HAE)
NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.
Onxeo encouraged by intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA in combination with chemotherapy
Onxeo said it stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ plus carboplatin, with reaching satisfactory tolerance allowing the continuation of the study to evaluate AsiDNA™ in combination with carboplatin and paclitaxel, a reference treatment protocol for many cancers.
Versantis closes CHF 16M series B financing round to advance clinical development of novel therapeutics for liver diseases
Versantis has closed a series B financing round, and plans to use the funds to fuel the completion of ongoing Phase 1b studies with VS-01 and advance its clinical development up to clinical proof-of-efficacy (phase 2a) in 2 indications.
Schreiner MediPharm has launched a new tamper-evident security concept for luer-lock syringes: Cap-Lock features a combination of a cap adapter and label that firmly seals prefilled syringes and reliably indicates any first opening.
Anokion Presents New Data Describing Transformative Therapeutic Approach for Treatment of Multiple Sclerosis at ECTRIMS Congress
Induction of Antigen-Specific Immune Tolerance Using Proprietary Technology Represents Novel, Targeted Treatment Modality for Autoimmune Diseases CAMBRIDGE, Mass. & LAUSANNE,